This stock no longer trades (delisted January 15, 2026)

Delisted / no longer publicly traded (per market data provider) Everything below is based on the last available data — treat it as historical, not a live read.

Mind Medicine (MindMed)

MNMD

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Winston Score History

The full picture

MindMed is a clinical-stage biotechnology company that develops medicines based on psychedelic compounds to treat mental health conditions. Its main focus is MM120, a purified form of LSD being tested as a treatment for generalized anxiety disorder. The company targets patients who have not responded well to existing psychiatric drugs, and its work sits within a broader wave of research exploring psychedelics as legitimate medical treatments.

MindMed does not yet sell any products, so it currently earns no revenue. It funds its operations through stock offerings and relies entirely on clinical trial success to eventually reach the market. The company is headquartered in New York and operates primarily in the United States and Canada. Its competitive position depends on being among the first to win FDA approval for a psychedelic-based prescription drug, but the main risk is that clinical trials could fail or regulatory approval could be delayed, which would require the company to keep raising cash to survive.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-188.0% YoY

YoY Growth Rate

Earnings declining

Insider Activity

2.8%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~5 years

$1.1B cash & investments

$1.1B cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-24.8%

Weak — -24.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial